Considering the subgroup of patients with colon cancer exhibiting phenotypes other than p21WAF1+/p53-, it seems that those with a low TS expression may more likely benefit from 5FU-based adjuvant therapy, whereas those with a high TS expression may not benefit because they already exhibit poor DFS and OS rates, despite having received 5FU-based therapy. The gene discussed is TYMS; the disease is colonic neoplasm.